U.S.-based pharmaceutical company Alexion says it will decrease the cost of Strensiq, a potentially life-saving treatment for paediatric-onset hypophosphatasia.
A recent guidance, however, paves the way for Strensiq to be used in treatment of both adults and children, according to a report by pharmaphorum.
The ultra-rare disease, according to the report, affects roughly seven people each year in England. Paediatric-onset hypophosphatasia “disrputs the process in which minerals such as calcium and phosphorus are deposited in developing bones,” per the report.
“We worked diligently and constructively with NICE, NHS England, advocates and physicians, and are extremely pleased that we were able to reach an agreement to make Strensiq available to patients with paediatric-onset HPP in England who are most in need of treatment,” Alexion CEO Ludwig Hantson said.